Resveratrol is a poly-phenol with many beneficial effects: not only as an antioxidant, anti-inflammatory, and
antiatherogenic agent, as well as a platelet aggregation inhibitor, but also as an antiproliferative and proapoptotic factor in
various types of cancers. There are reviews about the mechanisms responsible for its effects in leukemia and lymphomas,
emphasizing the chemosensitizing role of resveratrol, which allows overcoming the multidrug resistance of cancers. The
action of resveratrol occurs preferentially on leukemic cells, and not on the normal ones. In addition, it is one of the few
drugs that act on leukemic stem cells. If experimental results are promising, its application in humans encounters some
difficulties. The paper presents the causes of its low bioavailability, as well as recent patents that allow improvement of its
bioavailability, development of new extraction procedures, obtaining new formulae, and associating resveratrol with other
drugs in order to increase its effects. These patents allow optimizing its effects in order to obtain an adjuvant agent for
treatment of oncohematological disorders.
Keywords: Antioxidant, apoptosis, leukemia, lymphoma, minimal residual disease, multidrug resistance, proliferation, resveratrol.
Rights & PermissionsPrintExport